Odyssey Therapeutics (NASDAQ:ODTX) Stock Rating Upgraded by Raymond James Financial

Odyssey Therapeutics (NASDAQ:ODTX) was upgraded by equities research analysts at Raymond James Financial to a “moderate buy” rating in a research report issued on Thursday, Zacks reports.

A number of other research firms also recently issued reports on ODTX. Oppenheimer reiterated an “outperform” rating and set a $40.00 target price on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. Weiss Ratings initiated coverage on Odyssey Therapeutics in a report on Tuesday, August 11th. They set a “sell (d+)” rating for the company. Wall Street Zen lowered shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 20th. JPMorgan Chase & Co. boosted their price target on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, HC Wainwright initiated coverage on Odyssey Therapeutics in a research note on Thursday, August 27th. They issued a “buy” rating and a $44.00 price objective on the stock. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $37.00.

Odyssey Therapeutics Stock Performance

Shares of NASDAQ ODTX opened at $19.00 on Thursday. Odyssey Therapeutics has a 52-week low of $15.10 and a 52-week high of $29.05. The company has a 50 day simple moving average of $22.76. The firm has a market cap of $913.14 million and a PE ratio of -2.81.

Odyssey Therapeutics (NASDAQ:ODTX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter. On average, analysts expect that Odyssey Therapeutics will post -6.20 EPS for the current year.

Institutional Investors Weigh In On Odyssey Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company purchased a new stake in Odyssey Therapeutics in the 2nd quarter worth approximately $601,000. State Street Corp bought a new stake in Odyssey Therapeutics during the second quarter worth about $1,477,000. Finally, Citadel Advisors LLC bought a new stake in Odyssey Therapeutics in the 2nd quarter worth approximately $4,162,000.

About Odyssey Therapeutics

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for serious diseases, with an emphasis on immunology and oncology. The company uses a combination of human genetics, functional genomics, computational biology, machine learning and medicinal chemistry to identify disease targets and advance potential therapeutic programs.

Odyssey’s research and development activities are centered on small-molecule medicines designed to address genetically validated targets and specific disease mechanisms.